Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
To donate a blood sample for cell preparation (procurement stage):
- People of any age or sex who have a type of lymphoma (Hodgkin's or non-Hodgkin's) or a related blood condition linked to a virus called EBV (Epstein-Barr virus), or a serious long-term EBV illness
- People whose tumor has tested positive for EBV, or where that test result is still pending
- People who weigh at least 12 kilograms (approximately 26 pounds)
- People (or their guardian) who have understood and signed a consent form
To receive the treatment (infusion stage):
- People of any age or sex with an EBV-linked lymphoma or related EBV illness, whose cancer has come back a second time or more, or in certain situations where standard chemotherapy is not safe to use, or who are in remission but considered high-risk for the disease returning (confirm with trial site for full details on which situation applies)
- People whose tumor has confirmed a positive EBV result
- People whose liver function, blood counts, and kidney function are within certain acceptable ranges as measured by blood tests (the trial site will check these)
- People whose blood oxygen level is above 90% while breathing normal room air
- People who have been off other experimental treatments for at least 4 weeks before joining (certain immune therapy drugs may still be allowed if a doctor considers them medically necessary)
- People who have a performance score of 50 or above on a standard medical activity scale, meaning they are able to manage at least some self-care (confirm with trial site)
- People who are sexually active and are willing to use effective birth control during the trial and for 6 months afterward
- People (or their guardian) who have understood and signed a consent form
Who may not be able to join:
At the donation stage:
- People with an active infection involving HIV, HTLV, hepatitis B, or hepatitis C (results may still be pending at this point)
At the treatment stage:
- People who are pregnant or currently breastfeeding
- People who have a serious active infection at the time of treatment
- People who are currently taking steroid medications (such as prednisone) at a dose above 0.5 mg per kilogram of body weight per day
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Helen E Heslop, MD, Baylor College of Medicine
Phone: 832-824-4662
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Assessment of toxicity of escalating doses of LMP, BARF1 and EBNA1 T lymphocytes
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.